정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1283 | Active, not recruiting | Hydroxychloroquine for Treatment of Non-Severe COVID-19 | Covid19 | Drug: Hydroxychloroquine tablets | Phase 2 | Makerere University | OTHER | 105 | All | 18 Years | Namboole COVID-19 treatment unit, Kampala, Uganda |
| 1282 | Not yet recruiting | Hydroxychloroquine in Combination With Sirolimus and Dexamethasone for Treating COVID-19 Patients | COVID-19 Patients | Drug: HCQ & AZ vs HCQ+SIR | Not Applicable | King Hussein Cancer Center | OTHER | 58 | All | 18 Years | King Hussein Cancer Center, Amman, Jordan |
| 1281 | Recruiting | Hydroxychloroquine in COVID-19 Patients | COVID-19 | Drug: Hydroxychloroquine | Phase 2 | Samah Lutfy | OTHER_GOV | 200 | All | 18 Years ~ 70 Years | SNH, Mecca, Saudi Arabia |
| 1280 | Terminated | Hydroxychloroquine in Outpatient Adults With COVID-19 | Coronavirus Infection | Drug: Hydroxychloroquine SAR321068 Drug: Placebo |
Phase 1 | Sanofi | INDUSTRY | 8 | All | 18 Years ~ 80 Years | Investigational Site Number 8400001, Boston, Massachusetts, United States Investigational Site Number 0561001, Bruxelles, Belgium Investigational Site Number 0561002, Lodelinsart, Belgium Investigational Site Number 2501001, Bordeaux Cedex, France Investigational Site Number 2501002, Paris, France Investigational Site Number 5281001, Groningen, Netherlands Investigational Site Number 5281002, Harderwijk, Netherlands |
| 1279 | Suspended | Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care | 2019 Novel Coronavirus | Drug: Hydroxychloroquine Dietary Supplement: Vitamin C |
Phase 4 | Providence Health & Services, Center for Outcomes Research and Education, Providence Cancer Center, Earle A. Chiles Research Institute | OTHER | 13 | All | 45 Years | Portland Providence Medical Center, Portland, Oregon, United States |
| 1278 | Withdrawn | Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial | COVID-19 | Drug: Hydroxychloroquine | Phase 4 | Kootenai Health, Washington State University | OTHER | 0 | All | 18 Years | Kootenai Health, Coeur d'Alene, Idaho, United States |
| 1277 | Completed | Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers | COVID-19 | Drug: Hydroxychloroquine | Phase 2 | Baylor Research Institute | OTHER | 221 | All | 18 Years ~ 75 Years | Baylor University Medical Center, Dallas, Texas, United States |